Back to results
US 12,636,344 B2Granted
Preferentially expressed antigen in melanoma (PRAME) T cell receptors and methods of use thereof
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsNatalie Bowerman, Johanna Hansen
Life of this patent
Estimating the term…
Abstract
The present invention provides isolated T cell receptors (TCRs) that specifically bind to an HLA-displayed cancer testis antigen preferentially expressed antigen in melanoma (FRAME) peptide, as well as therapeutic and diagnostic methods of using those isolated TCRs.
Claims30
A T cell receptor (TCR) that binds specifically to an HLA-A2 presented preferentially expressed antigen in melanoma (PRAME) peptide,
- wherein the TCR comprises a TCR alpha chain and a TCR beta chain, and
- wherein the TCR alpha chain comprises an alpha chain variable domain comprising a complementarity determining region (CDR) 1, a CDR2, and a CDR3 comprising the amino acid sequences of SEQ ID NOs:
- 493, 494, and 495, respectively, and the TCR beta chain comprises a beta chain variable domain comprising a CDR1, a CDR2, and a CDR3 comprising the amino acid sequences of SEQ ID NOs:
- 496, 497, and 498, respectively.
1 more element
Dependencies are inferred from the claim text.